Lundbeck partner soon to seek approval for new Abilify Maintena version

Japanese Otsuka, Lundbeck's partner in sharing rights for Abilify Maintena, signals plans to seek marketing approval for a longer-acting version of the drug – a move that could extend the medication's patent protection.
Photo: Thomas Borberg
Photo: Thomas Borberg
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN

The term of Abilify Maintena's patent protection could be substantially extended. Japanese Otsuka, Lundbeck's partner for the drug, is in the process of preparing to seek approval for a new and longer-acting version of the medication.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading